Ranbaxy Laboratories declines on reporting consolidated net loss of Rs 1029.72 crore in Q3

29 Jan 2015 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 689.50, down by 10.25 points or 1.46% from its previous closing of Rs. 699.75 on the BSE.

The scrip opened at Rs. 685.00 and has touched a high and low of Rs. 696.00 and Rs. 684.00 respectively. So far 49844 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 724.95 on 28-Jan-2015 and a 52 week low of Rs. 308.00 on 04-Feb-2014.

Last one week high and low of the scrip stood at Rs. 724.95 and Rs. 673.00 respectively. The current market cap of the company is Rs. 29387.81 crore.

The promoters holding in the company stood at 63.22 % while Institutions and Non-Institutions held 21.16 % and 15.61 % respectively.

Ranbaxy Laboratories reported a net loss of Rs 1420.48 crore for the quarter as compared to net loss of Rs 395.96 crore for the same quarter in the previous year. Total income of the company has decreased 25.92% at Rs 1027.6 crore for Q3FY15 as compared Rs 1387.16  crore for the corresponding quarter previous year.

On the consolidated basis, the group has reported a net loss after taxes and Minority Interest of Rs 1029.72 crore for the quarter as compared to net loss of Rs 158.94 crore for the same quarter in the previous year. Total income of the company has decreased by 10.23% at Rs 2629.52 crore for quarter under review as compared to Rs 2929.23 crore for the quarter ended December 31, 2013.

Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.